Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceritinib and SABR in ALK+ Lung Adenocarcinoma
NCT02513667Phase 2Terminated
- Sponsor
- UT Southwestern Medical Center
- Start
- Nov 2015
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ceritinib in lung adenocarcinoma, sponsored by UT Southwestern Medical Center. Started Nov 2015; status: terminated.
02
Drugs
ceritinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT02513667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02513667.